Autoimmune rheumatic diseases associated with granulomatous mastitis

Parperis, Konstantinos; Achilleos, Savvas; Costi, Egli; Vardas, Michail

doi:10.1007/s00296-022-05251-9

Cited by 11 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One theory is an autoimmune reaction to the secretion extravasated from lobules ( 2 ). Unexpected findings include the large number of cases without accompanying autoimmune disease, rare detection of vasculitis, plasma cell infiltration upon histologic examination, and very few cases presenting antinuclear antibodies and/or rheumatoid factors ( 3 , 4 ). Recent studies demonstrating immunologic dysregulation as the underlying etiology have inspired other studies focusing on detailed immunologic analysis of IGM ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Ozone therapy as a novel complementary therapeutic approach in refractory idiopathic granulomatous mastitis

et al. 2023

View full text Add to dashboard Cite

BackgroundAutoimmunity may play a major role in the pathogenesis of idiopathic granulomatous mastitis (IGM). The therapeutic potential of ozone therapy has recently been shown in rheumatological diseases, and this study aimed to assess the clinical efficacy of ozone therapy (OT) in refractory IGM.MethodsPatients with biopsy-verified IGM and incomplete response after steroid therapy (n = 47) between 2018 and 2021 were enrolled. Of these, 23 cases in cohort A had standard treatment with further steroid therapy (ST), and 24 were treated with systemic OT via autohemotherapy (AHT) in addition to steroid therapy (cohort B).ResultsThe median age was 33 years (range, 24–45). Patients in cohort B had a higher complete response rate after completion of a four-month ozone therapy than those in the ST-group (OT-group, 37.5% vs. ST-group, 0%; p = 0.002). At a median follow-up of 12 months (range, 12–35), the patients treated with OT had a lower one-year recurrence in the affected breast than cases in cohort A treated with ST (OT-group, 21% vs. ST-group, 70%; p = 0.001). No significant side effects were observed in patients in cohort B related to AHT. Furthermore, OT significantly decreased the total steroid treatment duration (median week of steroid use; 26 weeks in cohort A vs. 12 weeks in cohort B; p = 0.001).ConclusionSystemic OT increases the complete response rate and decreases the duration of steroid treatment in patients with refractory IGM. Therefore, ozone therapy is an effective, well-tolerated, and safe novel complementary therapeutic modality.

show abstract